InvestorsHub Logo
Followers 3
Posts 1221
Boards Moderated 0
Alias Born 10/03/2022

Re: JRoon71 post# 423886

Friday, 05/03/2024 10:24:48 AM

Friday, May 03, 2024 10:24:48 AM

Post# of 425254
Why don’t we have any sales is places like Australia, New Zealand, Netherlands, Sweden, and the Asian pacific countries? I thought we had approvals in all these places yet only sales in Spain and England. Seems like Spain got up and running quick but I hear nothing about these other countries. Sweden was approved two year ago.

In the Netherlands, the Dutch Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular events in adult statin-treated patients with established cardiovascular disease and elevated triglycerides (≥ 1,7 and ≤ 5,6 mmol/l).Aug 9, 2023

In the first national reimbursement deal Amarin has signed in Europe, Sweden agreed to cover the drug for statin-treated patients with established cardiovascular disease and elevated triglycerides, Amarin said Monday. Vascepa is branded as Vazkepa in Europe.
The Swedish reimbursement price, at 1,640 Swedish krona (about $175) per month, meets expectations and is high relative to the drug’s U.S. net price after discounts and rebates, Cantor Fitzgerald analyst Louise Chen wrote in a Monday note.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News